Ahrn B, Masmiquel L, Kumar H, Sargin M, Derving Karsbl J, Hald Jacobsen S, et al
Embryofetal mortality, structural abnormalities (e.g., visceral and skeletal abnormalities), and alterations to growth were observed in the offspring of rats who were administered semaglutide during organogenesis at dosages resulting in systemic exposures lower than the maximum recommended human dosage
The shelf life of semaglutide depends on whether the medication remains unopened or has been used, with specific timeframes established through FDA-approved stability testing
These symptoms tend to be mild to moderate and resolve or improve even with continued medication use (9,28,29)
Klinics services in Aspen, Colorado, remove these barriers
for those using semaglutide for weight management, this means monitoring expected effects on appetite and weight